OncoSec Medical Inc (ONCSQ)

[Titan V]

Despite their potential, some cons of CAR-T therapy, for which Celgene paid $1B to Juno to become a partner, are that they're not useful on solid tumors, can have severe side-effects, and are still a few years behind from Keytruda and Opdivo.

http://fortune.com/2015/06/30/celgene-juno-therapeutics-cancer/

Competitors are out there for OncoSec for sure but have some limitations one way or the other. IF ONCS can prove its worth in the solid tumor space with little side effects and latching onto an already FDA approved drug, it may get a similar if not better offer in the near future. GLTA.